Visalytics
Visalytics
approved EB-2 (NIW)

Senior Research Associate

Pharmacology · China · 2026-01-14

Processing Time
296 days
Decision Date
2026-01-14
Location
Texas
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to advance pharmacological research by improving drug-conjugate therapies to create more selective delivery vehicles for cancer treatment. This work focuses on engineering therapeutic payloads to concentrate in tumor cells while limiting exposure to healthy tissue, thereby reducing off-target effects and collateral damage.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The research addresses a critical tradeoff in cancer care by improving drug-conjugate therapies to make delivery more selective and less toxic.

2 Well-positioned to Advance the Endeavor Met

The petitioner is well-positioned due to their Ph.D., 25 peer-reviewed articles, and 977 citations showing independent reliance by other scientists.

3 Balance of Factors Met

The record linked sophisticated pharmacology to a clear public-health need, justifying a waiver of the job offer requirement.

Why This Petition Was Approved

The petition was approved based on the petitioner's Ph.D. in Pharmacology and a strong record of 25 peer-reviewed journal articles, 1 abstract, and 2 preprints. The work had garnered 977 citations, demonstrating independent reliance by the scientific community, and was supported by competitive funding from the NIH and CPRIT.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Independent
Grants
Government Alignment

Similar Cases

Postdoctoral Researcher

Pharmaceuticals · Bangladesh

WeGreened EB-2 (NIW) approved
Illinois 535 days 2026-01-16
The petitioner proposes to continue research in clinical pharmaceutical sciences, specifically focusing on understanding cancer development at the molecular level. The work involves investigating mechanisms such as genome instability and replication stress to identify actionable molecular targets for cost-conscious therapeutic strategies.
View Case

Postdoctoral Researcher

Biotechnology · India

WeGreened EB-2 (NIW) approved
Missouri 49 days 2025-04-01
The petitioner proposes to identify novel therapeutic targets to improve personalized medicine and enhance treatment outcomes for cancer patients. Her work focuses on addressing drug resistance in oncology by integrating synthetic biology, protein engineering, and tumor signaling analysis to develop optimized drug delivery methods.
View Case

Postdoctoral Researcher

Biotechnology · Taiwan

WeGreened EB-2 (NIW) approved
Maryland 26 days 2025-06-02
The petitioner proposes to continue research in cancer biology, specifically exploring the molecular mechanisms behind tumor progression and drug resistance. This work focuses on identifying novel therapeutic targets to inform the development of advanced combination therapies and precision medicine paradigms. The intended impact is to improve patient survival rates by creating safer and more effective treatment options for cancers that have evolved resistance to conventional therapies.
View Case

Research Scientist

Biotechnology · India

WeGreened EB-2 (NIW) approved
Indiana 296 days 2025-02-24
The petitioner proposes to develop targeted cancer therapeutics and precision-based therapeutic options to prevent the recurrence of malignant diseases. The work focuses on creating cost-effective, personalized, and immunological therapies to simplify cancer diagnosis and treatment. The endeavor aims to improve treatment outcomes, reduce side effects, and lower long-term healthcare costs in the United States.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from China

Case data sourced from publicly available petition decisions and case studies. Decision date: 2026-01-14.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 296 days
Criteria Met 3 / 3
Evidence Types 5

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,814
Success Rate 53.6%
Sustained 2,046
Dismissed 1,672

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in China All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist